{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:36:34Z","timestamp":1777545394013,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13023-017-0663-8","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T08:11:43Z","timestamp":1497687103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders"],"prefix":"10.1186","volume":"12","author":[{"given":"Kyeongsoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hynda K.","family":"Kleinman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hahn-Jun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalipada","family":"Pahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,17]]},"reference":[{"key":"663_CR1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","volume":"79","author":"RE Williams","year":"2012","unstructured":"Williams RE, Mole SE. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology. 2012;79:183\u201391.","journal-title":"Neurology"},{"key":"663_CR2","first-page":"2237","volume":"2015","author":"S Mole","year":"1852","unstructured":"Mole S, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (batten disease). Biochim Biophys Acta. 1852;2015:2237\u201341.","journal-title":"Biochim Biophys Acta"},{"key":"663_CR3","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/0883073813493665","volume":"28","author":"SB Dolisca","year":"2013","unstructured":"Dolisca SB, Mehta M, Pearce DA, Mink JW, Maria BL. Batten disease: clinical aspects, molecular mechanisms, translation science and future directions. J Child Neurol. 2013;28:1074\u2013100.","journal-title":"J Child Neurol"},{"key":"663_CR4","first-page":"1795","volume":"2013","author":"M Haltia","year":"1832","unstructured":"Haltia M, Goebel HH. The neuronal ceroid lipofuscinoses: historical introduction. Biochim Biophys Acta. 1832;2013:1795\u2013800.","journal-title":"Biochim Biophys Acta"},{"key":"663_CR5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/humu.21624","volume":"33","author":"M Kousi","year":"2012","unstructured":"Kousi M, Lehesjoki AE, Mole SE. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat. 2012;33:42\u201363.","journal-title":"Hum Mutat"},{"key":"663_CR6","first-page":"2242","volume":"2015","author":"J Carcel-Truillois","year":"1852","unstructured":"Carcel-Truillois J. Kovacs, AD, Pearce DA. Cell biology of the NCL proteins: what they do and don\u2019t do Biochim Biophys Acta. 1852;2015:2242\u201355.","journal-title":"Cell biology of the NCL proteins: what they do and don\u2019t do Biochim Biophys Acta"},{"key":"663_CR7","first-page":"2292","volume":"2015","author":"NJ Neverman","year":"1852","unstructured":"Neverman NJ, Best HL, Hofmann SL, Hughes SM. Experimental therapies in the neuronal ceroid lipofuscinoses. Biochim Biophys Acta. 1852;2015:2292\u2013300.","journal-title":"Biochim Biophys Acta"},{"key":"663_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13023-016-0414-2","volume":"11","author":"RD Geraets","year":"2016","unstructured":"Geraets RD, Koh SY, Hastings ML, Kielian T, Pearce DA, Weimer JM. Moving towards effective therapeutic strategies for neuronal ceroid lipofuscinosis. Orphanet J Rare Dis. 2016;11:40. doi: 10.1186\/s13023-016-0414-2 .","journal-title":"Orphanet J Rare Dis"},{"key":"663_CR9","first-page":"2336","volume":"2015","author":"SL Cotman","year":"1852","unstructured":"Cotman SL, Mole SE, Kohan R. Future perspectives: moving towards NCL treatments. Biochim Biophys Acta. 1852;2015:2336\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"663_CR10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.expneurol.2008.04.022","volume":"213","author":"D Sondhi","year":"2008","unstructured":"Sondhi D, Peterson DA, Edelstein AM, del Fierro K, Hackett NR, Crystal RG. Survival advantage of neonatal CNS gene transfer for late infantile neural ceroid lipofuscinosis. Exp Neurol. 2008;213:18\u201327.","journal-title":"Exp Neurol"},{"key":"663_CR11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","volume":"19","author":"S Worgall","year":"2008","unstructured":"Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, Neyzi N, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDAN. Hum Gen Ther. 2008;19:463\u201374.","journal-title":"Hum Gen Ther"},{"key":"663_CR12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1089\/hgtb.2012.120","volume":"23","author":"D Sondhi","year":"2012","unstructured":"Sondhi D, Johnson L, Purpura K, Monette S, Souweidande MM, Kaplitt MG, et al. Long term expression and safety of administration of AAVrh 10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinsis. Hum Gene Ther Methods. 2012;23:324\u201335.","journal-title":"Hum Gene Ther Methods"},{"key":"663_CR13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/hum.2005.16.741","volume":"16","author":"E Abordo-Adesida","year":"2005","unstructured":"Abordo-Adesida E, Follenzi A, Barcia C, Sciascia S, Castro MG, Naldini L, et al. Stability of lentiviral vector-mediated transgene expression in the brian in the presence of systemic antivector immune response. Hum Gene Ther. 2005;16:741\u201351.","journal-title":"Hum Gene Ther"},{"issue":"313","key":"663_CR14","doi-asserted-by":"crossref","first-page":"313ra180","DOI":"10.1126\/scitranslmed.aac6191","volume":"7","author":"ML Katz","year":"2015","unstructured":"Katz ML, Tecedor L, Chen Y, Williamson BG, Lysenko E, Wininger F, et al. AAV gene transfer delays disease onset in TPP1-deficient canine model of the late infantile form of batten disease. Sci Transl Med. 2015;7(313):313ra180.","journal-title":"Sci Transl Med"},{"key":"663_CR15","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1042\/BST0381484","volume":"38","author":"AM Wong","year":"2010","unstructured":"Wong AM, Rahim AA, Waddington SN, Cooper JD. Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis. Biochem Soc Trans. 2010;38:1484\u20138.","journal-title":"Biochem Soc Trans"},{"key":"663_CR16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/mt.2008.9","volume":"16","author":"M Chang","year":"2008","unstructured":"Chang M, Cooper JD, Sleat DE, Cheng SH, Dodge JC, Passini MA, et al. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal lipofuscinosis. Mol Ther. 2008;16:649\u201356.","journal-title":"Mol Ther"},{"key":"663_CR17","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ymgme.2009.12.002","volume":"99","author":"JY Lu","year":"2010","unstructured":"Lu JY, Hu J, Hofmann SL. Human recombinant palmitoyl-protein thioesterase-1 (PPT1) for preclinical evaluation of enzyme replacement therapy for infantile neuronal ceroid lipofuscinosis. Mol Gener Metab. 2010;99:374\u20138.","journal-title":"Mol Gener Metab"},{"key":"663_CR18","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/mt.2011.130","volume":"19","author":"S Xu","year":"2011","unstructured":"Xu S, Wang L, El-Banna M, Schar I, Sleat DE, Lobel P. Large volume intrathecal delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther. 2011;19:1842\u20138.","journal-title":"Mol Ther"},{"key":"663_CR19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ymgme.2012.05.009","volume":"107","author":"J Hu","year":"2012","unstructured":"Hu J, Lu JY, Wong AM, Hynan LS, Birnbaum SG, Yimaz DS, et al. Intravenous high dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase-1 reduces visceral lysosomal storage and modestly prolongs survival in a preclinical model of infantile neuronal ceroid lipofuscinosis. Mol Genet Metab. 2012;107:213\u201321.","journal-title":"Mol Genet Metab"},{"key":"663_CR20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ymgme.2014.09.004","volume":"114","author":"BR Vuillemenot","year":"2014","unstructured":"Vuillemenot BR, Kennedy D, Cooper JD, Wong AM, Sri S, Doeleman T, et al. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in a canine CLN2 neuronal ceroid lipofuscinosis. Mol Genet Metab. 2014;114:281\u201393.","journal-title":"Mol Genet Metab"},{"key":"663_CR21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jnr.23423","volume":"92","author":"MI Katz","year":"2014","unstructured":"Katz MI, Coates JR, Sibigtroth CM, Taylor JD, Carpentier M, Young WM, et al. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile ceroid lipofuscinosis (CLN2). J Neurosci Res. 2014;92:1591\u20138.","journal-title":"J Neurosci Res"},{"key":"663_CR22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbrc.2010.03.137","volume":"395","author":"G Dawson","year":"2010","unstructured":"Dawson G, Schroeder C, Dawson E. Palmitoyl thioesterase (PPT1) inhibitors can act a pharmacological chaperones in infantile batten disease. Biochim Biophys Res Commun. 2010;395:66\u20139.","journal-title":"Biochim Biophys Res Commun"},{"key":"663_CR23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2011.0370","volume":"9","author":"KJ Valenzano","year":"2011","unstructured":"Valenzano KJ, Khanna R, Powe AC, Boyd R, Lee G, Flanagan JJ, et al. Identification and characterization of pharmacological chaperones for correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev Technol. 2011;9:213\u201335.","journal-title":"Assay Drug Dev Technol"},{"key":"663_CR24","doi-asserted-by":"crossref","first-page":"42508","DOI":"10.1074\/jbc.M507380200","volume":"280","author":"MR Pears","year":"2005","unstructured":"Pears MR, Cooper JD, Mitchinson HM, Mortishire-Smither RJ, Pearce DA, Griffin JL. High resolution 3H NMR-based metabolomics indicates a neurotransmitter cycling defect in cerebral tissue from a mouse model of batten disease. J Biol Chem. 2005;280:42508\u201314.","journal-title":"J Biol Chem"},{"key":"663_CR25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.expneurol.2007.09.012","volume":"209","author":"AD Kovacs","year":"2008","unstructured":"Kovacs AD, Pearce DA. Attenuation of AMPA receptor activity improves motor skills in a mouse model of juvenile batten disease. Exp Neurol. 2008;209:288\u201391.","journal-title":"Exp Neurol"},{"key":"663_CR26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.neuropharm.2010.10.010","volume":"60","author":"AD Kovacs","year":"2011","unstructured":"Kovacs AD, Saje A, Wong A, Szenasi G, Kiricsi P, Szabo E, et al. Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile batten disease. Neuropharmacology. 2011;60:405\u20139.","journal-title":"Neuropharmacology"},{"key":"663_CR27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1474-4422(14)70142-5","volume":"13","author":"SW Levin","year":"2014","unstructured":"Levin SW, Baker EH, Zein WM, Zhang Z, Quezado ZM, Miao N, et al. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancer Neurol. 2014;13:777\u201387.","journal-title":"Lancer Neurol"},{"key":"663_CR28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jneuroim.2010.08.024","volume":"230","author":"SS Seehafer","year":"2011","unstructured":"Seehafer SS, Ramirez-Montealegre D, Wong AM, Chan CH, Castaneda J, Horak M, et al. Immunosuppression alters disease severity in juvenile batten disease mice. J Neuroimmunol. 2011;230:169\u201372.","journal-title":"J Neuroimmunol"},{"key":"663_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1742-2094-10-97","volume":"10","author":"GW Kay","year":"2013","unstructured":"Kay GW, Palmer DN. Chronic oral administration of mimocycline to sheep with ovine CLN6 neuronal ceroid lipofuscinsis maintsin pharmacological concentrations in the brain but does not suppress neuroinflammation or disease progression. J Neuroinflammation. 2013;10:97. doi: 10.1186\/1742-2094-10-97 .","journal-title":"J Neuroinflammation"},{"key":"663_CR30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-973677","volume":"28","author":"BD Lake","year":"1997","unstructured":"Lake BD, Steward CG, Oakhill A, Wilson J, Perham TG. Bone marrow transplantation in late infantile batten disease and juvenile batten disease. Neuropediatrics. 1997;28:80\u20131.","journal-title":"Neuropediatrics"},{"key":"663_CR31","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/WNL.57.8.1411","volume":"57","author":"T Lonnqvist","year":"2001","unstructured":"Lonnqvist T, Vanhanen SL. Hematopoietic stem cell transplantation in infantile neuroid lipofuscinosis. Neurology. 2001;57:1411\u20136.","journal-title":"Neurology"},{"key":"663_CR32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.stem.2009.05.022","volume":"5","author":"SJ Tamaki","year":"2009","unstructured":"Tamaki SJ. Jacobs Y, Dohse, Capela a, Cooper JD, Reitsman M, et al. Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell. 2009;5:310\u20139.","journal-title":"Cell Stem Cell"},{"key":"663_CR33","first-page":"873","volume":"1762","author":"JD Cooper","year":"2006","unstructured":"Cooper JD, Russell C, Mitchinson HM. Progress towards understanding disease mechanisms in small vertebrate models of neuronal ceroid lipofuscinosis. Biochem Bophys Acta. 2006;1762:873\u201389.","journal-title":"Biochem Bophys Acta"},{"key":"663_CR34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.exer.2015.02.012","volume":"134","author":"RE Whiting","year":"2015","unstructured":"Whiting RE, Pearce JW, Castaner LJ, Jensen CA, Katz RJ, Gilliam DH, et al. Multifocal retinopathy in dachshunds with CLN2 neuronal ceroid lipofuscinosis. Exp Eye Res. 2015;134:123\u201332.","journal-title":"Exp Eye Res"},{"issue":"supplement 2","key":"663_CR35","first-page":"6","volume":"69","author":"G Rodney","year":"1976","unstructured":"Rodney G, Uhlendorf P, Maxwell RE. The hypolipemic effect of gemfibrozil (CL-719) in laboratory animals. Proc R Soc Med. 1976;69(supplement 2):6\u201310.","journal-title":"Proc R Soc Med"},{"key":"663_CR36","doi-asserted-by":"crossref","first-page":"34134","DOI":"10.1074\/jbc.M112.398552","volume":"287","author":"M Jana","year":"2012","unstructured":"Jana M, Mondal S, Gonzalez FJ, Pahan K. Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-\u03b2. J Biol Chem. 2012;287:34134\u201348.","journal-title":"J Biol Chem"},{"key":"663_CR37","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s11064-012-0781-6","volume":"37","author":"M Jana","year":"2012","unstructured":"Jana M, Pahan K. Gemfibrozil, a lipid lowering drug, inhibits the activation of primary human microglia via peroxisome proliferator-activated receptor \u03b2. Neurochem Res. 2012;37:1718\u201329.","journal-title":"Neurochem Res"},{"key":"663_CR38","first-page":"28922","volume":"287","author":"A Ghosh","year":"2012","unstructured":"Ghosh A, Corbett GT, Gonzalex FJ, Pahan K. Gemfibrozil and fenobrate, Food and Drug Administration-approved lipid lowering drugs, upregulate tripeptidyl peptidase 1 in brain cells via peroxisome proliferation activated receptor \u03b1. J Biol Chem. 2012;287:28922\u201338935.","journal-title":"J Biol Chem"},{"key":"663_CR39","doi-asserted-by":"crossref","first-page":"10309","DOI":"10.1074\/jbc.M114.610659","volume":"290","author":"A Ghosh","year":"2015","unstructured":"Ghosh A, Jana M, Modi K, Gonzales FJ, Sims K, Berry-Kravis E, et al. Activation of peroxisome proliferator-activated receptor induces lysosomal biogenesis in brain cells. J Biol Chem. 2015;290:10309\u201324.","journal-title":"J Biol Chem"},{"key":"663_CR40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/08923970902785253","volume":"31","author":"A Roy","year":"2009","unstructured":"Roy A, Pahan K. Gemfibrozil, stretching arms beyond lipid lowering. Immuno pharm Immuno Tox. 2009;31:339\u201351.","journal-title":"Immuno pharm Immuno Tox"},{"key":"663_CR41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fphar.2016.00206","volume":"7","author":"Y Ashikawa","year":"2016","unstructured":"Ashikawa Y, Nishimura Y, Okabe S, Sasagawa S, Murakami S, Yuge M, et al. Activation of sterol regulatory element binding factors by fenofibrate and gemfibrozil stimulates myelination in zebrafish. Front Pharmacol. 2016;7:206. https:\/\/doi.org\/10.3389\/fphar.2016.00206","journal-title":"Front Pharmacol"},{"key":"663_CR42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1248\/bpb.20.315","volume":"20","author":"F Hashimoto","year":"1997","unstructured":"Hashimoto F, Hamada S, Hayahsi H. Effect of gemfibrozil on centrifugal behavior of rat peroxisomes and activity of peroxiosmal enzymes involved in lipid metabolism. Biol Pharm Bull. 1997;20:315\u201321.","journal-title":"Biol Pharm Bull"},{"key":"663_CR43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","volume":"325","author":"M Sardiello","year":"2009","unstructured":"Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, et al. A gene network regulating lysosomal biogenesis and functions. Science. 2009;325:473\u20137.","journal-title":"Science"},{"key":"663_CR44","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1093\/hmg\/ddr306","volume":"20","author":"M Palmieri","year":"2011","unstructured":"Palmieri M, Impey S, Kang D, di Ronza A, Pelz C, Sardiello M, et al. Characterization of the CLAR network reveals an integrated control of cellular clearance pathways. Hum Mol Genet. 2011;20:3852\u201366.","journal-title":"Hum Mol Genet"},{"key":"663_CR45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.devcel.2011.07.016","volume":"21","author":"DL Medina","year":"2011","unstructured":"Medina DL, Fraldi A, Bouche V, Annunziata F, Mansueto G, Spampanato C, et al. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell. 2011;21:421\u201330.","journal-title":"Dev Cell"},{"key":"663_CR46","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/hmg\/ddt052","volume":"22","author":"W Song","year":"2013","unstructured":"Song W. Wang, Savini M, Ake a, di Ronza a, Sardiello M, et al. TFEB regulates lysosomal proteostasis. Hum Mol Genet. 2013;22:1994\u20132009.","journal-title":"Hum Mol Genet"},{"key":"663_CR47","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/hmg\/ddt596","volume":"23","author":"X Lowjewski","year":"2014","unstructured":"Lowjewski X, Starpoli JF, Biswas-Legrand S, Simas A, Haliw L, Selig MK, et al. Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. Huma Mol Genet. 2014;23:2005\u201322.","journal-title":"Huma Mol Genet"},{"key":"663_CR48","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11626-015-9979-7","volume":"52","author":"M Hong","year":"2016","unstructured":"Hong M, Song KD, Lee H-K, Yi S, Lee YS, Heo T-H, et al. Fibrates inhibit the apoptosis of batten disease lymphoblast cells via autophagy recovery and regulation of mitochondrial membrane potential. In vitro Cell Dev Biol. 2016;52:349\u201355.","journal-title":"In vitro Cell Dev Biol"},{"key":"663_CR49","first-page":"423","volume":"14","author":"A Ghosh","year":"2016","unstructured":"Ghosh A, Rangasamy S, Khushbu M, Pahan K. 2016 Gemfibrozil, Food and Drug Administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem. 2016;14:423\u201335.","journal-title":"J Neurochem"},{"key":"663_CR50","unstructured":"Buyukcelik M, Anarat A, Bayazit AK, Noyan A, Ozel A, Anarat R, et al. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome. Turk J Pediatr 2002;44:40-44."},{"key":"663_CR51","first-page":"1063","volume":"46","author":"PK Jalkrishan","year":"2009","unstructured":"Jalkrishan PK, Narang A. Gemfibrozil in late preterm and term neonates with moderate jaundice: a randomized controlled trial. Indian Pediatric. 2009;46:1063\u20139.","journal-title":"Indian Pediatric"},{"key":"663_CR52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jacl.2008.02.003","volume":"2","author":"CM Smalley","year":"2008","unstructured":"Smalley CM, Smalley AB, Goldberg SJ. A pilot study in the efficacy and safety of gemfibrozil in a pediatric population. J Clin Lipidology. 2008;2:106\u201311.","journal-title":"J Clin Lipidology"},{"key":"663_CR53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40272-013-0028-2","volume":"15","author":"MJ Kennedy","year":"2013","unstructured":"Kennedy MJ, Jellerson KD, Snow MZ, Zacchetti ML. Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents. Pediatr Drugs. 2013;15:335\u201342.","journal-title":"Pediatr Drugs"},{"key":"663_CR54","doi-asserted-by":"publisher","first-page":"807434","DOI":"10.1155\/2010\/807434","volume":"2010","author":"HA Azkawi","year":"2010","unstructured":"Azkawi HA, AlAlwan I. Two siblings with familial chylomiconemia syndrome: disease course and effectiveness of early treatment. Case Rep Med. 2010;2010:807434. doi: 10.1155\/2010\/807434 .","journal-title":"Case Rep Med"},{"key":"663_CR55","first-page":"207","volume":"20","author":"B Abtahi-Naeini","year":"2015","unstructured":"Abtahi-Naeini B, Sadeghiyan H, Adibi N, Shokrollahi MR, Pourazizi M. Bullous dermatosis of childhood induced by gemfibrozil. J Res Med Sci. 2015;20:207\u20138.","journal-title":"J Res Med Sci"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0663-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T07:03:20Z","timestamp":1569481400000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-017-0663-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,17]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["663"],"URL":"https:\/\/doi.org\/10.1186\/s13023-017-0663-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,17]]},"article-number":"113"}}